Forma Therapeutics Holdings Profit Margin 2019-2021 | FMTX

Current and historical gross margin, operating margin and net profit margin for Forma Therapeutics Holdings (FMTX) over the last 10 years. Profit margin can be defined as the percentage of revenue that a company retains as income after the deduction of expenses. Forma Therapeutics Holdings net profit margin as of June 30, 2021 is 0%.
Forma Therapeutics Holdings Annual Profit Margins
Forma Therapeutics Holdings Quarterly Profit Margins
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.864B $0.101B
Forma Therapeutics Holdings Inc. is a clinical-stage biopharmaceutical company. It is focused on the development and commercialization of novel therapeutics with rare hematologic diseases and cancers. Forma Therapeutics Holdings Inc. is based in Watertown, United States.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $127.972B 8.52
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $11.985B 20.30
Biohaven Pharmaceutical Holding (BHVN) United States $8.378B 0.00
Emergent Biosolutions (EBS) United States $2.740B 6.61
Arcus Biosciences (RCUS) United States $2.509B 0.00
Myovant Sciences (MYOV) United Kingdom $1.869B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.763B 0.00
Zymeworks (ZYME) Canada $1.061B 0.00
Ambrx Biopharma (AMAM) United States $0.501B 0.00
SQZ Biotechnologies (SQZ) United States $0.333B 0.00
Enzo Biochem (ENZ) United States $0.157B 15.43